(Reuters) - The latest results included a gain of 57 cents a share from the sale of the company's branded drug business in Europe.
Analysts on average had expected a profit of $1.12 a share before one-time items, according to Reuters Estimates.
Read more at Reuters.com Business News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment